glp 1 agonist uses Another milestone in the evolution of GLP-1-based diabetes therapies Benefits and drawbacks of GLP-1

48 Similarly, among obese individuals without diabetes, semaglutide use was shown to increase the risk of developing GI adverse events by 1.59 times compared with the control group

The online pharmacies segment accounted for the largest share of the global market in 2024 due to its unparalleled convenience, allowing patients to order their medications from the comfort of their homes

[cited 2025 May 28]

Evidence from dual-energy X-ray absorptiometry and MRI sub-studies suggests that 2545% of total weight loss with semaglutide and tirzepatide may come from reductions in lean body mass

This explosive growth of Ozempic lawsuits filed (from 346 cases in mid-2024 to nearly 3,000 by late 2025) reflects increasing awareness as patients linked Ozempic to severe complications and learned about the legal avenues available for seeking compensation